Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
7.49
+0.61 (8.87%)
Jan 22, 2025, 4:00 PM EST - Market closed
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 500 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
500
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$130,368
Profits / Employee
-$755,502
Market Cap
2.95B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 500 | 0 | - |
Dec 31, 2022 | 500 | 100 | 25.00% |
Dec 31, 2021 | 400 | 69 | 20.85% |
Dec 31, 2020 | 331 | 131 | 65.50% |
Dec 31, 2019 | 200 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
RXRX News
- 15 days ago - Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More - GlobeNewsWire
- 16 days ago - Recursion to Present at 43rd Annual JP Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 5 weeks ago - Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform - Seeking Alpha
- 6 weeks ago - Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability - GlobeNewsWire
- 6 weeks ago - Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245 - Seeking Alpha
- 2 months ago - Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery - GlobeNewsWire
- 2 months ago - Recursion and Exscientia Shareholders Approve the Proposed Combination - GlobeNewsWire